UNSPSC 51141580: Sultiame

This classification denotes an anticonvulsant and thiazine with the molecular formula C10H14N2O4S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I00Q766CZ2, chemically known as 2-(p-sulfamoylphenyl)-tetrahydro-2h-1,2-thiazine 1,1-dioxide but generally known as sultiame, which bears US NIH Compound Identifier 5356. European Medicines Agency schedules Sultiame in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10762MIG.

World Health Organization schedules sultiame in its Anatomical Therapeutic Chemical (ATC) Classification. SULTIAME is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule sultiame under HS 29350090 and SITC 51580. SMILES: C1CCS(=O)(=O)N(C1)C2=CC=C(C=C2)S(=O)(=O)N.

UNSPSC 51141580 Sultiame is a Commodity code that encompasses pharmaceutical products, though the recent state and local opportunities tagged under this code show a significant mismatch with the narrow nominal scope. The three recent solicitations address naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and multi-source generic pharmaceuticals and over-the-counter products — a much broader pharmaceutical procurement landscape than sultiame (an anticonvulsant medication) alone would suggest. State and local buyers under this code include county health departments, state health and human services agencies, and cooperative purchasing alliances. The work being solicited ranges from emergency-response consumables (naloxone kits) to ongoing pharmacy benefit management and pharmaceutical supply agreements with multiple vendors, reflecting both tactical public-health procurement and strategic statewide contracting for medication access.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued an IFB (Solicitation IFB60459723LAS, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to a county health building, requiring electronic bid submission and including a three-month probationary period with FEMA compliance requirements. The Texas Health and Human Services Commission posted an RFI (HHS0017013, April 3, 2026) to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, functioning as preliminary market intelligence before formal procurement. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products with distribution through three authorized wholesalers, an effective date of July 1, 2026, and weighted evaluation criteria favoring price competitiveness at 75 percent. The code shows modest recent activity and does not consistently track the nominal sultiame commodity — vendors should verify relevance before pursuing opportunities tagged under this code.